Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

"Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development fo

r the Treatment of Hereditary Angioedema

Company Plans to Use Private Placement Financing Proceeds of $110 Million to Complete IND-Enabling Studies, Pha

se 1a and Phase 1b/2 Clinical Trials of QLS-215..."

020121 Catabasis Pharmaceuticals Announc

.

Download • 243KB